A study examines using oral challenges to diagnose acetaminophen ingestion allergies.
Oral challenge tests (OCTs) in 60 children referred to a clinic in Turkey with a suspected history of acetaminophen hypersensitivity verified hypersensitivity to the drug in 8 patients. Conversely, skin tests for acetaminophen hypersensitivity produced only 1 positive reaction, which turned out to be a false positive.
Skin prick tests with acetaminophen were administered to participants, who had a median age of 8.5 years, with positivity defined as producing a wheal with a diameter at least 3mm or larger than the negative control after 20 minutes. Investigators also checked for delayed type reactions. For the OCTs, 4 escalating doses of the culprit drug (either acetaminophen or acetaminophen/ibuprofen) were administered orally at 30-minute intervals until a cumulative dose was reached without triggering any symptoms. The OCT was considered negative if it produced no reaction during the test or when patients continued to take the drug for 3 days at home. The cumulative doses were 15mg/kg/dose and 10mg/kg/dose for acetaminophen and ibuprofen, respectively.
In those with verified acetaminophen hypersensitivity, an OCT with a strong COX-1 inhibitor was performed to classify the type of the reaction as either selective- or cross-intolerance-hypersensitivity. A subsequent OCT with a selective COX-2 inhibitor was performed in those cross-intolerant patients to find a safe alternative drug (Cimen SS, et al. Pediatr Allergy Immunol. August 12, 2020; Epub ahead of print).
Thoughts from Dr. Farber
I have 2 points to make here. First, although I was aware that aspirin allergy is well known, I had not heard of allergy being an issue with acetaminophen. Second, this study is a reminder that the true test for an ingestion allergy, when doubt exists, is an OCT (done in a safe setting).
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
September 13th 2024The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.